Ortho Clinical Diagnostic: Q4 Earnings Insights
$OCDX
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Health Care
Ortho Clinical Diagnostic (NASDAQ:OCDX) reported its Q4 earnings results on Wednesday, February 16, 2022 at 04:30 PM.
Here's what investors need to know about the announcement.
Earnings
Ortho Clinical Diagnostic beat estimated earnings by 20.0%, reporting an EPS of $0.18 versus an estimate of $0.15.
Revenue was up $4.40 million from the same period last year.
Past Earnings Performance
Last quarter the company beat on EPS by $0.07, which was followed by a 4.84% increase in the share price the next day.
Here's a look at Ortho Clinical Diagnostic's past performance:
| Quarter | Q3 2021 | Q2 2021 | Q1 2021 | Q4 2020 |
|---|---|---|---|---|
| EPS Estimate | 0.14 | 0.14 | 0.16 | 0.20 |
| EPS Actual | 0.21 | 0.16 | 0.26 | 0.19 |
| Revenue Estimate | 481.71M | 475.86M | 477.53M | 508.01M |
| Revenue Actual | 522.50M | 492.50M | 506.80M | 516.60M |
To track all upcoming earnings announcements, click to use Benzinga Earnings Calendar.
This article was generated by Benzinga's automated content engine and reviewed by an editor.